{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:58:11Z","timestamp":1792799891663,"version":"4.5.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T00:00:00Z","timestamp":1709424000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Atopic dermatitis (AD) is a chronic inflammatory skin disorder impacting populations worldwide, although its clinical characteristics and patient demographics remain uncharacterized in China. The aim of this study was to investigate the demographics, comorbidities, aggravating factors, and treatments in AD patients across different age groups in China.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This cross-sectional study included Chinese AD patients from 205 hospitals spanning 30 provinces. Patients completed dermatologist-led surveys of general medical history, comorbidities, AD-related aggravating factors, and medications. Two-level mixed-ordered logistic regression was used to evaluate aggravating factors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Overall, 16,838 respondents were included in the final analysis (aged 30.9 \u00b1 24.1 years). The proportion of severe AD was the highest in patients with AD onset at \u226560 years (26.73%). Allergic rhinitis and hypertension were the most common atopic and metabolism-related non-atopic comorbidities, respectively. AD severity was significantly associated with chronic urticaria, food allergies, and diabetes. Aggravating factors including foods, seasonal changes, and psychological factors were also linked to AD severity. The cross-sectional survey implied that severe AD may be related to the undertreatment of effective systemic or topical interventions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>To enhance the management of AD, it is crucial to consider both aggravating factors and the increased utilization of systemic immunotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Registration:<\/jats:title>\n            <jats:p>\n                                 ClinicalTrials.gov, NCT05316805<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003042","type":"journal-article","created":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T00:00:27Z","timestamp":1709424027000},"page":"553-561","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Associations of demographics, aggravating factors, comorbidities, and treatments with atopic dermatitis severity in China: A national cross-sectional study"],"prefix":"10.1097","volume":"138","author":[{"given":"Jiahui","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Dermatology, Peking University First Hospital, Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, National Clinical Research Center for Skin and Immune Disease, NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Peking University First Hospital, Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, National Clinical Research Center for Skin and Immune Disease, NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongguang","family":"Chen","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Mental Health, Peking University Sixth Hospital, Beijing 100191, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Dou","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuotao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Peking University First Hospital, Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, National Clinical Research Center for Skin and Immune Disease, NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Peking University First Hospital, Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, National Clinical Research Center for Skin and Immune Disease, NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Peking University First Hospital, Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, National Clinical Research Center for Skin and Immune Disease, NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Peking University First Hospital, Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, National Clinical Research Center for Skin and Immune Disease, NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Beijing 100034, China"},{"name":"Center for Clinical Big Data of National Clinical Medical Research Center for Skin and Immune Disease, National Institute of Health Data Science, Beijing 100191, China"},{"name":"Peking University\u2013Yunnan Baiyao International Medical Research Center, Beijing 100871, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,3,3]]},"reference":[{"key":"R1-20250828","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jid.2016.08.022","article-title":"Increasing comorbidities suggest that atopic dermatitis is a systemic disorder","volume":"137","author":"Brunner","year":"2017","journal-title":"J Invest Dermatol"},{"key":"R2-20250828","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jaci.2009.10.009","article-title":"Global variations in prevalence of eczema symptoms in children from ISAAC phase three","volume":"124","author":"Odhiambo","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"R3-20250828","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/all.13401","article-title":"Epidemiology of atopic dermatitis in adults: Results from an international survey","volume":"73","author":"Barbarot","year":"2018","journal-title":"Allergy"},{"key":"R4-20250828","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jaci.2017.05.031","article-title":"Patterns and predictors of atopic dermatitis disease control past childhood: An observational cohort study","volume":"141","author":"Abuabara","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"R5-20250828","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/all.13320","article-title":"The prevalence of atopic dermatitis beyond childhood: A systematic review and meta-analysis of longitudinal studies","volume":"73","author":"Abuabara","year":"2018","journal-title":"Allergy"},{"key":"R6-20250828","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","article-title":"Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study","volume":"126","author":"Silverberg","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R7-20250828","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40257-019-00453-7","article-title":"Adult-onset atopic dermatitis: Characteristics and management","volume":"20","author":"Vakharia","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"R8-20250828","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13223-019-0398-2","article-title":"Epidemiology and associated factors of atopic dermatitis in Malagasy children","volume":"16","author":"Sendrasoa","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"R9-20250828","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/ijd.15912","article-title":"Atopic dermatitis in adults: A population-based study in Finland","volume":"61","author":"Kiiski","year":"2022","journal-title":"Int J Dermatol"},{"key":"R10-20250828","doi-asserted-by":"crossref","first-page":"e184145","DOI":"10.1001\/jamanetworkopen.2018.4145","article-title":"Incidence trends of atopic dermatitis in infancy and early childhood in a nationwide prescription registry study in Norway","volume":"1","author":"Mohn","year":"2018","journal-title":"JAMA Netw Open"},{"key":"R11-20250828","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1186\/s12889-022-13650-7","article-title":"Time-trends for eczema prevalences among children and adults from 1985 to 2015 in China: A systematic review","volume":"22","author":"Liu","year":"2022","journal-title":"BMC Public Health"},{"key":"R12-20250828","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s13555-021-00516-w","article-title":"Epidemiology and characterization of atopic dermatitis in East Asian populations: A systematic review","volume":"11","author":"Cheng","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R13-20250828","doi-asserted-by":"crossref","first-page":"29751","DOI":"10.1038\/srep29751","article-title":"Prevalence of atopic dermatitis in Chinese children aged 1-7 ys","volume":"19","author":"Guo","year":"2016","journal-title":"Sci Rep"},{"key":"R14-20250828","doi-asserted-by":"crossref","first-page":"100604","DOI":"10.1016\/j.waojou.2021.100604","article-title":"The prevalence and year lived with disability of atopic dermatitis in China: Findings from the global burden of disease study 2019","volume":"14","author":"Dong","year":"2021","journal-title":"World Allergy Organ J"},{"key":"R15-20250828","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jaci.2019.05.040","article-title":"Clinical onset of atopic eczema: Results from 2 nationally representative British birth cohorts followed through midlife","volume":"144","author":"Abuabara","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"R16-20250828","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bjd.18652","article-title":"Atopic dermatitis in the elderly: A review of clinical and pathophysiological hallmarks","volume":"182","author":"Williamson","year":"2020","journal-title":"Br J Dermatol"},{"key":"R17-20250828","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2133.1994.tb08530.x","article-title":"The U.K. working party\u2019s diagnostic criteria for atopic dermatitis. I. derivation of a minimum set of discriminators for atopic dermatitis","volume":"131","author":"Williams","year":"1994","journal-title":"Br J Dermatol"},{"key":"R18-20250828","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jaad.2015.09.062","article-title":"A systematic review of investigator global assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standards","volume":"74","author":"Futamura","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R20-20250828","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","article-title":"Atopic dermatitis in America study: A cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population","volume":"139","author":"Chiesa Fuxench","year":"2019","journal-title":"J Invest Dermatol"},{"key":"R21-20250828","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/jdv.13301","article-title":"The effect of environmental humidity and temperature on skin barrier function and dermatitis","volume":"30","author":"Engebretsen","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R22-20250828","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jaci.2014.06.034","article-title":"Total transcriptome, proteome, and allergome of Johnson grass pollen, which is important for allergic rhinitis in subtropical regions","volume":"135","author":"Campbell","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"R23-20250828","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jaci.2015.04.015","article-title":"Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber","volume":"136","author":"Werfel","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"R24-20250828","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/pde.12867","article-title":"Study of the atopic march: Development of atopic comorbidities","volume":"33","author":"Schneider","year":"2016","journal-title":"Pediatr Dermatol"},{"key":"R25-20250828","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.anai.2018.07.042","article-title":"Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in us adults","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R26-20250828","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jamadermatol.2014.3059","article-title":"Central obesity and high blood pressure in pediatric patients with atopic dermatitis","volume":"151","author":"Silverberg","year":"2015","journal-title":"JAMA Dermatol"},{"key":"R27-20250828","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/bjd.20802","article-title":"Atopic dermatitis, hypertension and cardiovascular disease","volume":"186","author":"Abdallah","year":"2022","journal-title":"Br J Dermatol"},{"key":"R28-20250828","doi-asserted-by":"crossref","first-page":"e67890","DOI":"10.1371\/journal.pone.0067890","article-title":"Does stress increase the risk of atopic dermatitis in adolescents? Results of the Korea youth risk behavior web-based survey (kyrbws-vi)","volume":"8","author":"Kwon","year":"2013","journal-title":"PLoS One"},{"key":"R29-20250828","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jaci.2018.08.005","article-title":"Sleep disorders and atopic dermatitis: A 2-way street?","volume":"142","author":"Chang","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"R30-20250828","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jaad.2022.01.009","article-title":"American Academy of Dermatology guidelines: Awareness of comorbidities associated with atopic dermatitis in adults","volume":"86","author":"Davis","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"R31-20250828","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/jdv.14891","article-title":"Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: Part I","volume":"32","author":"Wollenberg","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R32-20250828","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"R33-20250828","doi-asserted-by":"crossref","first-page":"497","DOI":"10.5021\/ad.2021.33.6.497","article-title":"Consensus update for systemic treatment of atopic dermatitis","volume":"33","author":"Lee","year":"2021","journal-title":"Ann Dermatol"},{"key":"R34-20250828","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents","volume":"71","author":"Sidbury","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"R35-20250828","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jaad.2022.12.029","article-title":"Guidelines of care for the management of atopic dermatitis in adults with topical therapies","volume":"89","author":"Sidbury","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"R36-20250828","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/j.clinthera.2004.11.017","article-title":"Relationship between systemic corticosteroid exposure and growth velocity: Development and validation of a pharmacokinetic\/pharmacodynamic model","volume":"26","author":"Daley-Yates","year":"2004","journal-title":"Clin Ther"},{"key":"R37-20250828","doi-asserted-by":"crossref","first-page":"o1618","DOI":"10.1136\/bmj.o1618","article-title":"NICE recommends three more treatments for atopic dermatitis","volume":"377","author":"Wise","year":"2022","journal-title":"BMJ"},{"key":"R38-20250828","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s12016-020-08802-9","article-title":"Current and future monoclonal antibodies in the treatment of atopic dermatitis","volume":"59","author":"Chun","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"R39-20250828","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.anai.2020.08.016","article-title":"New treatments in atopic dermatitis","volume":"126","author":"Puar","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R40-20250828","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK inhibitors in the treatment of atopic dermatitis","volume":"148","author":"Chovatiya","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"R41-20250828","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1111\/j.1365-2230.2009.03719.x","article-title":"A randomized double-blind controlled trial to compare a triclosan-containing emollient with vehicle for the treatment of atopic dermatitis","volume":"35","author":"Tan","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"R42-20250828","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1468-3083.2010.03616.x","article-title":"Efficacy and tolerability of pale sulfonated shale oil cream 4% in the treatment of mild to moderate atopic eczema in children: A multicentre, randomized vehicle-controlled trial","volume":"24","author":"Korting","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T15:01:19Z","timestamp":1756393279000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,3]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003042","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,3]]},"assertion":[{"value":"2023-12-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}